相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Outpatient therapeutic nuclear oncology
J. Harvey Turner
ANNALS OF NUCLEAR MEDICINE (2012)
Automated Module Radiolabeling of Peptides and Antibodies with Gallium-68, Lutetium-177 and Iodine-131
Mario De Decker et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2012)
Radiologic Reviews: More Second Guessing From Armchairs Cannot Lead the Way
Erard M. Gilles
JOURNAL OF CLINICAL ONCOLOGY (2012)
Prospective Study of Bevacizumab Plus Temozolomide in Patients With Advanced Neuroendocrine Tumors
Jennifer A. Chan et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Progression-Free Survival: Meaningful or Simply Measurable?
Christopher M. Booth et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Peptides and Receptors in Image-Guided Therapy: Theranostics for Neuroendocrine Neoplasms
Richard P. Baum et al.
SEMINARS IN NUCLEAR MEDICINE (2012)
Sunitinib in advanced pancreatic neuroendocrine tumors: latest evidence and clinical potential
Catherine Delbaldo et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2012)
First-Line Chemotherapy With Capecitabine and Temozolomide in Patients With Metastatic Pancreatic Endocrine Carcinomas
Jonathan R. Strosberg et al.
CANCER (2011)
Phase II study of radiopeptide 177Lu-octreotate and capecitabine therapy of progressive disseminated neuroendocrine tumours
Phillip G. Claringbold et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2011)
Future Directions in the Treatment of Neuroendocrine Tumors: Consensus Report of the National Cancer Institute Neuroendocrine Tumor Clinical Trials Planning Meeting
Matthew H. Kulke et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study
Marianne E. Pavel et al.
LANCET (2011)
Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors.
Eric Raymond et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Everolimus for Advanced Pancreatic Neuroendocrine Tumors.
James C. Yao et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
O-6-Methylguanine DNA Methyltransferase Deficiency and Response to Temozolomide-Based Therapy in Patients with Neuroendocrine Tumors
Matthew H. Kulke et al.
CLINICAL CANCER RESEARCH (2009)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients With Metastatic Neuroendocrine Midgut Tumors: A Report From the PROMID Study Group
Anja Rinke et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Highly Efficient In Vivo Agonist-Induced Internalization of sst(2) Receptors in Somatostatin Target Tissues
Bea Waser et al.
JOURNAL OF NUCLEAR MEDICINE (2009)
One hundred years after Carcinoid: Epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States
James C. Yao et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Treatment with the radiolabeled somatostatin analog [177Lu-DOTA0, Tyr3] octreotate:: Toxicity, efficacy, and survival
Dik J. Kwekkeboom et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors
Sara Ekeblad et al.
CLINICAL CANCER RESEARCH (2007)
Therapeutic options for gastrointestinal carcinoids
Irvin M. Modlin et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2006)
Validation of a personalized dosimetric evaluation tool (Oedipe) for targeted radiotherapy based on the Monte Carlo MCNPX code
S Chiavassa et al.
PHYSICS IN MEDICINE AND BIOLOGY (2006)
A software tool for specifying voxel models for dosimetry estimation
E McKay
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2003)
Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use
JC Reubi et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE (2000)
分享论文
